leadf
logo-loader
AIM:MXCT

MaxCyte Inc

Receive alerts
Market:
AIM
Market Cap:
£274.69 m
Price
356.00 GBX
Change
0.00%
52 weeks high
376.00
52 weeks low
95.00

In brief

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

Snapshot

  • Pioneering work in gene editing to tackle cancer
  • "Highly optimistic" during coronavirus crisis
  • Over 100 cell therapy licences with partners, including 11 at the clinical stage

 

Insight Widest with the analysis, Proactive gives perspectives that others don't.